[go: up one dir, main page]

PE20010935A1 - Compuestos antitromboticos - Google Patents

Compuestos antitromboticos

Info

Publication number
PE20010935A1
PE20010935A1 PE2000001308A PE0013082000A PE20010935A1 PE 20010935 A1 PE20010935 A1 PE 20010935A1 PE 2000001308 A PE2000001308 A PE 2000001308A PE 0013082000 A PE0013082000 A PE 0013082000A PE 20010935 A1 PE20010935 A1 PE 20010935A1
Authority
PE
Peru
Prior art keywords
pentasacarido
spacer
refers
antithrombotic compounds
pentascarido
Prior art date
Application number
PE2000001308A
Other languages
English (en)
Inventor
Tamara Theodora Maria Geertsen
Boeckel Constant Adriaan Anton Van
Cornelia Maria Tromp
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of PE20010935A1 publication Critical patent/PE20010935A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A CONJUGADOS QUE CONTIENE PENTASACARIDOS DE FORMULA I DONDE R ES SO3(-), CH3; EL ESPACIADOR ES FLEXIBLE DE 13-25 ATOMOS (NO CONTIENE INSATURACIONES, ESTRUCTURAS CICLICAS); LA CARGA DEL PENTASACARIDO ES COMPENSADA POR LOS CONTRAIONES CARGADOS POSITIVAMENTE (H(+), Na(+), K(+), Ca(+2)); Y EL NUMERO TOTAL DE SULFATOS EN EL RESIDUO DE PENTASACARIDO ES 4, 5 o 6. EL ESPACIADOR ES *-(CH2CH2O)3-(CH2)2-NH-C(O)-(CH2)3-NH-C(O)-CH2- ESTANDO EL EXTREMO INDICADO CON * UNIDO AL RESIDUO PENTASACARIDO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE UNA ETAPA EN QUE LA PORCION BENZAMIDINA ESTA EN LA FORMA DE UN PRECURSOR QUE ES EL GRUPO 1,2,4-OXADIAZOLIN-5-ONA. EL COMPUESTO ES UTIL PARA PREVENIR O TRATAR LA TROMBOSIS
PE2000001308A 1999-12-07 2000-12-06 Compuestos antitromboticos PE20010935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99204172 1999-12-07

Publications (1)

Publication Number Publication Date
PE20010935A1 true PE20010935A1 (es) 2001-09-20

Family

ID=8240976

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001308A PE20010935A1 (es) 1999-12-07 2000-12-06 Compuestos antitromboticos

Country Status (23)

Country Link
US (1) US6875755B2 (es)
EP (1) EP1237897B1 (es)
JP (1) JP4820517B2 (es)
KR (1) KR100776607B1 (es)
CN (1) CN1195767C (es)
AR (1) AR026726A1 (es)
AU (1) AU781846B2 (es)
BR (1) BR0016217A (es)
CA (1) CA2393042C (es)
CO (1) CO5251449A1 (es)
CZ (1) CZ303385B6 (es)
HK (1) HK1047593A1 (es)
HU (1) HUP0203471A3 (es)
IL (2) IL149628A0 (es)
NO (1) NO323059B1 (es)
NZ (1) NZ519100A (es)
PE (1) PE20010935A1 (es)
PL (1) PL202840B1 (es)
RU (1) RU2266913C2 (es)
SK (1) SK287682B6 (es)
TW (1) TWI289566B (es)
WO (1) WO2001042262A2 (es)
ZA (1) ZA200203799B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1440077T3 (da) * 2001-09-07 2013-07-08 Alchemia Ltd Syntetiske heparinpentasaccharider
US7208498B2 (en) 2002-07-15 2007-04-24 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
DE60315687T2 (de) 2002-10-07 2008-06-05 Merck & Co., Inc. Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase
PL376822A1 (pl) * 2002-11-07 2006-01-09 Merck & Co., Inc. Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy
CA2512546A1 (en) 2003-01-17 2004-08-05 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2004210149A1 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2524531A1 (en) 2003-05-14 2004-12-02 Merck And Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2526770A1 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2004249163A1 (en) 2003-06-17 2004-12-29 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1651623B1 (en) 2003-07-31 2008-12-17 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1574516A1 (en) * 2004-03-05 2005-09-14 Sanofi-Aventis Antithrombotic compound
TW200621794A (en) * 2004-10-06 2006-07-01 Akzo Nobel Nv Pulmonary administration of an antithrombotic compound
TWI403334B (zh) * 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
JP5060486B2 (ja) * 2005-10-10 2012-10-31 エム・エス・ディー・オス・ベー・フェー ビオチン標識を含む抗凝固抗血栓二重阻害剤
BR112012015016B8 (pt) 2009-12-18 2021-05-25 Catalent France Beinheim Sa formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
DE4206858A1 (de) * 1992-03-05 1993-09-09 Behringwerke Ag Glycopeptid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel
FR2704226B1 (fr) * 1993-04-22 1995-07-21 Sanofi Elf 3-desoxy oligosaccharides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
DK0649854T3 (da) * 1993-09-01 2000-07-03 Akzo Nobel Nv Biskonjugater omfattende to saccharider og en spacer
IL126893A (en) * 1997-11-19 2003-05-29 Akzo Nobel Nv Sulfated pentasaccharide derivatives and pharmaceutical compositions containing them
SK286755B6 (sk) * 1998-06-17 2009-05-07 Universiteit Leiden Antitrombotické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie

Also Published As

Publication number Publication date
CZ303385B6 (cs) 2012-08-29
CZ20021958A3 (cs) 2002-08-14
NZ519100A (en) 2004-09-24
CA2393042A1 (en) 2001-06-14
NO323059B1 (no) 2006-12-27
HUP0203471A2 (hu) 2003-02-28
WO2001042262A3 (en) 2001-12-13
AR026726A1 (es) 2003-02-26
TWI289566B (en) 2007-11-11
HK1047593A1 (zh) 2003-02-28
IL149628A0 (en) 2002-11-10
US20030114361A1 (en) 2003-06-19
PL202840B1 (pl) 2009-07-31
CO5251449A1 (es) 2003-02-28
US6875755B2 (en) 2005-04-05
WO2001042262A2 (en) 2001-06-14
NO20022689L (no) 2002-06-06
KR20020070988A (ko) 2002-09-11
SK7942002A3 (en) 2002-09-10
HUP0203471A3 (en) 2003-03-28
BR0016217A (pt) 2002-09-10
JP2003520208A (ja) 2003-07-02
ZA200203799B (en) 2003-10-29
KR100776607B1 (ko) 2007-11-16
RU2266913C2 (ru) 2005-12-27
SK287682B6 (sk) 2011-06-06
CA2393042C (en) 2011-06-28
EP1237897A2 (en) 2002-09-11
IL149628A (en) 2010-04-29
AU781846B2 (en) 2005-06-16
CN1195767C (zh) 2005-04-06
CN1407989A (zh) 2003-04-02
JP4820517B2 (ja) 2011-11-24
PL355484A1 (en) 2004-05-04
NO20022689D0 (no) 2002-06-06
AU2003801A (en) 2001-06-18
EP1237897B1 (en) 2015-01-14

Similar Documents

Publication Publication Date Title
PE20010935A1 (es) Compuestos antitromboticos
ES2017647B3 (es) Nuevos tioeteres fenolicos como inhibidores de 5-lipoxigenasa.
BRPI9912175A (pt) peptídios de antígeno cd4-cdr2, composição farmacêutica compreendendo os mesmos bem como uso da mesma
AR023920A1 (es) COMPUESTOS DE TRIAZOLO[4,5-D]PIRIMIDINA, COMPOSICION FARMACEUTICA, USO DE DICHOS COMPUESTOS PARA PREPARAR MEDICAMENTOS, Y PROCESO PARA LA PREPARACION DE DICHOS COMPUESTOS Y COMPUESTOS uTILES COMO INTERMEDIARIOS
BR0007781A (pt) Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf
GT199900022A (es) Compuestos para el tratamiento de la isquemia
BRPI0412314A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
BR0116309A (pt) Um método para descelularizar material estranho para produzir biopróteses
BR9914167A (pt) Composto, método de tratamento, inibição do crescimento de, ou erradicação de neoplasmas, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e processo para preparar o composto
ES2160897T3 (es) Pirazoles como inhibidores de la secretora fosfolipasa a2 humana no pancreatica.
BRPI0109131B8 (pt) dna, vetor de expressão compreendendo o mesmo, fator viii modificado de porcino, seu processo de produção e composição terapêutica compreendendo o mesmo
BR0005266A (pt) Compostos para o tratamento de disfução sexual feminina
ES2055159T3 (es) Composiciones que inducen la union entre partes de tejido mineralizado vivo.
PE20010962A1 (es) Derivados de heterociclo-alquilsulfonil-pirazol como agentes anti-inflamatorios/analgesicos
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
KR960022506A (ko) 피롤 유도체
AR013838A1 (es) Compuestos de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b]benzodiazepina-dihidratos; los dihidratos b,d y e de dicho compuesto y proceso para preparar la forma ii sustancialmente pura de la olanzapina a partir de dichos dihidratos
BR9916504A (pt) Hidroxamatos de sulfonamida
KR900016167A (ko) 아릴-치환된 로다닌 유도체
DE60016181D1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
ES2156633T3 (es) Derivados del acido tiazolidina-4-carboxilico como agentes citoprotectores.
ES2107806T3 (es) Nuevos esteroides.
BR0002505A (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
BR0010381A (pt) Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
AR009429A1 (es) Compuestos fenoles y tiofenoles sustituidos utiles como agentes antioxidantes y usos para la fabricacion de medicamentos

Legal Events

Date Code Title Description
FG Grant, registration
AE Restoration of lapsed or forfeited application
FG Grant, registration
FD Application declared void or lapsed